Clinical outcomes and complications associated with surgical resection of chest wall sarcoma.

Introduction: Chest wall sarcomas are rare malignant mesenchymal tumors arising from soft tissue, cartilage and bones. Wide resection is usually the treatment option but often results in postoperative complications after resection of the chest wall. In this study, we reviewed cases of chest wall sarcoma treated with resection of the sternum or ribs and examined the factors that could cause complications.

Epidemiology and Outcomes of Retroperitoneal Sarcoma: An Analysis of the Population-Based Cancer Registry in Japan 2016-2019.

Background: Retroperitoneal sarcoma (RPS) is a rare cancer, so few reports have previously characterized its national profiles. The capture rate of RPS in the Bone and Soft Tissue Tumor Registry was only 20%. The present study aimed to clarify the characteristics and clinical outcomes of RPS using the National Cancer Registry (NCR), which contains nationwide population-based data from Japan.

How Musculoskeletal Tumor Management Changed During the COVID-19 Pandemic: Data from a Nationwide Questionnaire Survey of Hospitals Specializing in Musculoskeletal Tumors in Japan.

Background: While changes in clinical practice during the COVID-19 pandemic in Japan have been widely studied, data specific to bone and soft tissue tumor care remain limited.

Methods: A nationwide web-based survey was conducted among hospitals specializing in musculoskeletal tumors. It assessed the occurrence of COVID-19-related events (patient infections, outbreak clusters, and staff infections), delays in referral and diagnosis, postponement or cancellation of specific treatments, and changes in institutional management strategies.

A comparative analysis of hand sarcoma by anatomical site: A case series.

Hand sarcomas are very rare, and few studies have focused on their anatomical distribution, such as involvement of the fingers vs. the palm/dorsum (PD). The present study reviewed 24 cases of hand sarcomas identified from medical records of National Cancer Centre Hospital (Tokyo, Japan) between January 2010 and December 2022, examining sex, age, maximum tumour size, metastasis, histology, origin (bone vs.

Favorable response to nivolumab combined with radiotherapy for retroperitoneal leiomyosarcoma.

Unlabelled: Retroperitoneal sarcoma (RPS) is a biologically heterogeneous tumor and rare malignant mesenchymal soft-tissue neoplasm. Although the 5-year overall survival rate for RPS is approximately 60%-70%, it is quite low for unresectable tumors. Surgery is a standard treatment for RPS.

Incidence and age- and site-specific characteristics of osteosarcoma: a population-based study using National Cancer Registry 2016-2019.

Background: No previous reports have characterized national profiles of osteosarcoma. In this study, we examined nationwide statistics for osteosarcoma in Japan using data from the National Cancer Registry (NCR), a population-based cancer registry launched in 2016.

Methods: We identified 1187 patients with osteosarcomas entered in the NCR during 2016-2019 using the cancer topography and morphology codes from the International Classification of Diseases for Oncology, Third Edition.

The prognostic factors and treatment patterns of the first recurrence of retroperitoneal liposarcoma.

Background: This study aimed to identify prognostic factors and treatment patterns at the first recurrence of retroperitoneal liposarcoma (LPS).

Methods: Medical records of 150 patients who underwent resection for primary retroperitoneal LPS were reviewed. Of the 94 patients with local or distant recurrence, prognostic factors and treatment approaches were retrospectively analyzed.

Proposal for a New Classification of Rare Cancers Adopting Updated Histological Tumor Types.

Several classifications have been proposed to define rare cancers; however, the pathophysiological understanding of tumors evolves rapidly. We propose a New Classification of Rare Cancer (NCRC) using the updated International Classification of Diseases for Oncology 3.2 coding system and World Health Organization Classification of Tumors 5th edition.

Prognostic potential of fusion gene analysis using plasma cell-free RNA in malignant bone and soft tissue tumours.

Background: Liquid biopsy, which facilitates minimally invasive analysis of body fluid samples, has considerable potential as a diagnostic and prognostic tool in various cancers. Analysis of circulating tumour cells, circulating tumour DNA, and exosomes in liquid biopsies has advantages and disadvantages. However, their utility in rare cancers, such as malignant bone and soft tissue tumours, remains unknown.

Incidence and site specific characteristics of angiosarcoma in Japan using a population-based national cancer registry from 2016 to 2019.

Angiosarcoma is so rare, no reports on its epidemiology and prognosis using nationwide population-based data exist. The present study aimed to clarify the characteristics and clinical outcomes of angiosarcoma using the National Cancer Registry (NCR) in Japan. We analyzed data from 23,522 patients with soft-tissue sarcomas (STS), entered in the NCR in 2016-2019 using the International Classification of Diseases-Oncology, Third Edition cancer topography and morphology codes.

Examining the Impact of Biopsy Technique on Clinical and Pathologic Outcomes in Dermatofibrosarcoma Protuberans: An International, Multi-Institutional Study.

Background: The National Comprehensive Cancer Network (NCCN) guidelines recommend preoperative biopsy for diagnosing dermatofibrosarcoma protuberans (DFSP) but limited data support this approach. We characterized DFSP diagnostic practices and compared clinical outcomes based on technique.

Methods: Data were collected for adult patients who underwent resection for initial DFSP presentation between 2003 and 2021 at 10 international institutions.

Prognostic factors and management of elderly sarcoma in Japan: the population-based National Cancer Registry (NCR) in Japan.

Background: In aging societies like Japan, the number of elderly bone sarcoma (BS) and soft-tissue sarcoma (STS) patients is increasing. However, these malignancies' behavior is incompletely understood. We investigated clinical features, treatment modalities, survival, and prognostic factors for elderly BS and STS patients using Japan's National Cancer Registry (NCR).

Chondrosarcoma in Japan: an analytic study using population-based National Cancer Registry.

Background: Chondrosarcoma (CS) is a rare malignant bone tumor exhibiting diverse histological features and clinical behaviors. This study aimed to investigate the epidemiological characteristics, clinical features, prognostic factors, and subtype-specific differences of CS in Japan using National Cancer Registry data.

Methods: We analyzed data from CS cases diagnosed between 2016 and 2019, calculating age-adjusted incidence, estimating overall survival, and identifying prognostic factors through multivariate analysis.

Identifying consensus and areas for future research in chondrosarcoma : a report from the Birmingham Orthopaedic Oncology Meeting.

Aims: The Birmingham Orthopaedic Oncology Meeting (BOOM), held in January 2024, convened 309 delegates from 53 countries to discuss and refine 21 consensus statements on the optimal management of chondrosarcoma.

Methods: With representation from Europe (43%; n = 133), North America (17%; n = 53), South America (16%; n = 49), Asia (13%; n = 40), Australasia (5%; n = 16), the Middle East (4%; n = 12), and Africa (2%; n = 6), the combined experience of treating bone sarcomas among attendees totalled approximately 30,000 cases annually, equivalent to 66 years of experience in the UK alone. The meeting's process began with the formation of a local organizing committee, regional leads, and a scientific committee comprising representatives from 150 specialist units across 47 countries.

Establishment and characterization of NCC-GCTB14-C1 and NCC-GCTB15-C1: two novel patient-derived cell lines of giant cell tumor of bone.

Giant cell tumor of bone (GCTB) is a rare bone tumor that is genetically characterized by a unique mutation in the H3-3A gene. Curative surgical resection is the standard treatment. Unfortunately, a considerable proportion of patients with GCTB have local recurrence and pulmonary metastasis after surgical treatment, and current chemotherapy treatments have shown non-effective.

Analysis of cancer multigene panel testing for osteosarcoma in pediatric and adults using the center for cancer genomics and advanced therapeutics database in Japan.

Background: Osteosarcoma (OS) is the most common primary malignant bone tumor. Despite advances in multimodal chemotherapy, prognosis for metastatic or recurrent OS remains poor. Next-generation sequencing (NGS) can uncover new therapeutic options by identifying potentially targetable alterations.

Identification of ENO-1 positive extracellular vesicles as a circulating biomarker for monitoring of Ewing sarcoma.

The lack of circulating biomarkers for tumor monitoring is a major problem in Ewing sarcoma management. The development of methods for accurate tumor monitoring is required, considering the high recurrence rate of drug-resistant Ewing sarcoma. Here, we describe a sensitive analytical technique for tumor monitoring of Ewing sarcoma by detecting circulating extracellular vesicles secreted from Ewing sarcoma cells.

Statistics of Visceral Sarcoma in Japan: Report From the Population-Based National Cancer Registry (NCR) in Japan.

Background And Objectives: Sarcomas developing in the visceral organs are extremely rare, with no previous reports to describe their national epidemiology. We analyzed Japanese domestic statistics for visceral sarcoma, using the National Cancer Registry (NCR) in Japan, a population-based database launched in 2016.

Methods: We identified 3245 cases of visceral sarcomas in the NCR dated 2016-2019 to analyze demographic and disease information, initial diagnostic process, volume and type of the hospitals, treatment, and prognosis.

Establishment and characterization of two novel patient-derived cell lines from myxofibrosarcoma: NCC-MFS7-C1 and NCC-MFS8-C1.

Myxofibrosarcoma (MFS), an aggressive soft tissue sarcoma, presents a significant challenge because of its high recurrence rate, distal metastasis, and complex genetic background. Although surgical resection is the standard treatment for MFS, the outcomes are unsatisfactory and effective non-surgical treatment strategies, including drug therapy, are urgently warranted. MFS is a rare tumor that requires comprehensive preclinical research to develop promising drug therapies; however, only two MFS cell lines are publicly available worldwide.

Clear cell sarcoma in Japan: an analysis of the population-based cancer registry in Japan.

Background: Clear cell sarcoma is rare, so no reports have previously characterized its national profiles. We examined the nationwide epidemiology and clinical outcomes of patients with clear cell sarcoma based on the National Cancer Registry in Japan.

Methods: Overall, 23 522 patients with soft tissue sarcoma-entered in the National Cancer Registry in 2016-2019 using the International Classification of Diseases for Oncology, Third Edition cancer topography and morphology codes-were enrolled in either the clear cell or the non-clear cell sarcoma group.

Establishment and characterization of NCC-SS6-C1: a novel patient-derived cell line of synovial sarcoma.

Synovial sarcoma (SS) is identified as a sarcoma with monomorphic blue spindle cells that display variable epithelial differentiation and is characterized by the SS18::SSX fusion gene. SS accounts for approximately 5-10% of all soft tissue sarcomas, making it a relatively common type within this group of tumors. Since SS is generally sensitive to chemotherapy, the standard treatment for SS includes extensive surgical resection, complemented by neoadjuvant chemotherapy with several approved anticancer drugs.

Utilizing the Metaverse to Provide Innovative Psychosocial Support for Pediatric, Adolescent, and Young Adult Patients with Rare Cancer.

This study investigated the potential of the metaverse in providing psychological support for pediatric and AYA cancer patients, with a focus on those with rare cancers. The research involved ten cancer patients and survivors from four distinct regions in Japan, who participated in metaverse sessions using customizable avatars, facilitating interactions across geographical and temporal barriers. Surveys and qualitative feedback were collected to assess the psychosocial impact of the intervention.

The diagnostic and prognostic value of tartrate-resistant acid phosphatase isoform 5b for giant cell tumor of bone.

Background: Serum level of tartrate-resistant acid phosphatase 5b (TRACP5b) is an excellent serum marker of bone resorption. In patients with giant cell tumor of bone (GCTB), TRACP5b levels are reportedly elevated. This study investigated whether TRACP5b could be a diagnostic serum marker and be useful for detecting postoperative disease progression for GCTB.